Sybil, a new AI tool developed by researchers from MIT and Mass General Brigham Cancer Institute, “analyzes a single CT scan and generates a risk score predicting the likelihood of developing lung cancer over a period of up to six years,” reports Ivan Rodriguez for WCVB-TV. “In 2023, researchers reported that Sybil achieved an accuracy rate of 86% to 94% in distinguishing high-risk patients from low-risk patients within a year.”
Reporting for CNN, Caleb Hellerman spotlights how MIT computer scientists developed an AI program called Sybil that can “‘look’ at a single CT scan and generate a ‘risk score’ corresponding to the likelihood of the person developing cancer over any period up to six years.”
Researchers at MIT have developed “mini livers” that “can be injected into the body to help take over the functions of a failing liver,” reports Ian Randall for Newsweek. “If realized clinically, the development could provide a lifeline for many of the more than 10,000 Americans with chronic liver disease currently waiting for a transplant,” writes Randall.
Prof. Robert Langer, Prof. Giovanni Traverso and former postdoctoral fellow Thomas von Erlach founded Vivtex, a biotechnology startup that has “created a high-tech system called a ‘GI tract on a chip’ that uses robotics and AI to test how drugs move through the human digestive system,” reports Beth Treffeisen for Boston.com. “The technology allows Vivtex to quickly test thousands of drug formulations and predict how they will be absorbed in people, much more accurately than traditional lab methods.”
Profs. Robert Langer, Giovanni Traverso and former postdoctoral fellow Thomas von Erlach have founded Vivtex, a biotechnology startup specializing in “oral alternatives to drugs administered by injections,” reports Jonathan Satlzman for The Boston Globe. Vivtex, now working in collaboration with Novo Nordisk, is looking to develop a new class of “pills to treat obesity and diabetes,” explains Saltzman.
Prof. Angela Belcher and Prof. Sangeeta Bhatia chat with Edgar B. Herwick III of GBH’s The Curiosity Desk about their efforts aimed at improving diagnostics for ovarian cancer. “We now know that ovarian cancer doesn’t originate in the ovaries. About 80% of the time, ovarian cancer starts in the fallopian tubes, but it can sit there as this precancerous lesion,” explains Belcher. “There’s new technologies that can be invented and developed to detect it much earlier, because if it’s detected earlier…there’s such an opportunity to make an impact.”
MIT researchers have developed a new method to fortify foods and beverages as part of an effort to combat global malnutrition, reports Insha Naureen for Food Ingredients First. “The innovation offers a potential solution to the global malnutrition crisis due to iron deficiency, which can lead to anemia, impaired brain development in children, and increased infant mortality,” Naureen explains. “Beyond iron and iodine, this platform can also deliver multiple micronutrients or bioactive compounds in a single formulation, enabling targeted nutritional strategies,” explains Ana Jaklenec, a principal investigator at the Koch Institute.
Researchers at MIT have developed a new nutrient fortification process “to deliver essential nutrients such as iron and iodine in foods and drinks,” reports Ben Cornwell for New Food Magazine. “With around two billion people worldwide suffering from iron deficiency, which can lead to anemia, impaired brain development in children and higher infant mortality, this solution from MIT could address a major global issue,” writes Cornwell.
Researchers at MIT have designed an implantable device that can be used to administer a dose of glucagon to protect Type 1 diabetics from hypoglycemia, reports Amir Khollam. “The device, about the size of a quarter, sits under the skin and releases a dose of glucagon when blood sugar levels dip too low,” explains Khollam. “It can be activated manually or triggered wirelessly by a sensor.”
Researchers at MIT have developed a new HIV vaccine that could offer “strong protection with just one injection,” reports Ian Randall for Newsweek. “The vaccine includes two ‘adjuvants’—materials that help stimulate the immune system response,” explains Randall. “In the experiments, the dual-adjuvant vaccine was found to produce a wider diversity of antibodies to protect against an HIV protein than with either single adjuvant or none at all.”
Woods Hole Film Festival will showcase “Cracking the Code: Phil Sharp and the Biotech Revolution,” a film highlighting Prof. Emeritus Phil Sharp’s academic journey and discovery of RNA splicing, reports Erin Trahan for WBUR. The festival runs from July 26 – August 2 in Falmouth, MA.
Scientific American reporter Nic Flemming spotlights research by Prof. Ömer Yilmaz and his team, which explores the impact of fasting on intestinal stem cells. “Both caloric restriction and fasting improved intestinal stem-cell activity and health, but the mechanisms involved are very different,” says Yilmaz.
MIT has multiple projects represented in this year’s STAT Madness, a bracket-style competition “highlighting important scientific advances emerging from labs at the nation’s universities, medical schools, and other U.S. research institutions and companies,” reports STAT staff.
MIT Profs. Angela Belcher, Emery Brown, Paula Hammond and Feng Zhang have been honored with National Medals of Science and Technology, reports Michael T. Neitzel for Forbes. Additionally, R. Lawrence Edwards '76 received a National Medal of Science and Noubar Afeyan PhD '87, a member of the MIT Corporation, accepted a National Medal on behalf of Moderna. The recipients have been awarded “the nation’s highest honors for exemplary achievements and leadership in science and technology,” explains Neitzel.
A new study led by researchers at MIT suggests that fasting and then refeeding stimulates cell regeneration in the intestines, reports Katharine Lang for Medical News Today. However, notes Lang, researchers also found that fasting “carries the risk of stimulating the formation of intestinal tumors.”